Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Published

Journal Article

BACKGROUND: Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need. METHODS: We conducted a phase 3, randomized, open-label study involving patients infected with HCV genotype 1 who had not had a sustained virologic response after treatment with peginterferon and ribavirin, with or without a protease inhibitor. Patients were randomly assigned to receive the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofosbuvir in a once-daily, fixed-dose combination tablet for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS: Among the 440 patients who underwent randomization and were treated, 20% had cirrhosis and 79% had HCV genotype 1a infection. The rates of sustained virologic response were high in all treatment groups: 94% (95% confidence interval [CI], 87 to 97) in the group that received 12 weeks of ledipasvir-sofosbuvir; 96% (95% CI, 91 to 99) in the group that received 12 weeks of ledipasvir-sofosbuvir and ribavirin; 99% (95% CI, 95 to 100) in the group that received 24 weeks of ledipasvir-sofosbuvir; and 99% (95% CI, 95 to 100) in the group that received 24 weeks of ledipasvir-sofosbuvir and ribavirin. No patient discontinued treatment owing to an adverse event. The most common adverse events were fatigue, headache, and nausea. CONCLUSIONS: Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologic response to prior interferon-based treatment. (Funded by Gilead Sciences; ION-2 ClinicalTrials.gov number, NCT01768286.).

Full Text

Duke Authors

Cited Authors

  • Afdhal, N; Reddy, KR; Nelson, DR; Lawitz, E; Gordon, SC; Schiff, E; Nahass, R; Ghalib, R; Gitlin, N; Herring, R; Lalezari, J; Younes, ZH; Pockros, PJ; Di Bisceglie, AM; Arora, S; Subramanian, GM; Zhu, Y; Dvory-Sobol, H; Yang, JC; Pang, PS; Symonds, WT; McHutchison, JG; Muir, AJ; Sulkowski, M; Kwo, P; ION-2 Investigators,

Published Date

  • April 17, 2014

Published In

Volume / Issue

  • 370 / 16

Start / End Page

  • 1483 - 1493

PubMed ID

  • 24725238

Pubmed Central ID

  • 24725238

Electronic International Standard Serial Number (EISSN)

  • 1533-4406

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1316366

Language

  • eng

Conference Location

  • United States